AI
PMN icon

Allostery Investments’s ProMIS Neurosciences PMN Stock Holding History

Allostery Investments’s Portfolio PMN Stock Details PMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,229
Closed -$76.3K – 16
2025
Q2 		$76.3K Sell
6,229
-3,119
-33% -$42.6K 0.97% 18
2025
Q1 		$165K Buy
9,348
+1,544
+20% +$32.8K 0.24% 35
2024
Q4 		$185K Buy
+7,804
New +$194K 0.19% 38

Other funds holding PMN

ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
HFS
Howard Financial Services Dallas, Texas $1B AUM 20.02% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Allostery Investments's PMN Position: Q3 2025 in Review

Allostery Investments sold out of ProMIS Neurosciences (PMN) in Q3 2025, closing a stake of 6,229 shares — an estimated $76.3K sold.

Allostery Investments first reported a position in PMN in Q4 2024 and held it in 3 quarters. The position peaked at $185K in Q4 2024. 23 funds tracked by Wall St. Rank hold PMN as of Q3 2025.

  • Allostery Investments reported no remaining ProMIS Neurosciences position as of Q3 2025 after selling out during the quarter.
  • Allostery Investments sold 6,229 ProMIS Neurosciences shares in Q3 2025, an estimated $76.3K.
  • Allostery Investments first reported a position in ProMIS Neurosciences in Q4 2024 and held it in 3 quarters.
  • Allostery Investments's ProMIS Neurosciences position peaked at $185K in Q4 2024.
  • 23 funds tracked by Wall St. Rank held ProMIS Neurosciences as of Q3 2025.

Based on Allostery Investments's 13F filing for Q3 2025.